Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.66 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.62 |
| ▸ | NOS2 | P35228 | 2/20 | 0.57 |
| ▸ | NOS1 | P29475 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285565 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL60520 | 1.00 | BHMT (0.66) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832133 | 0.94 | BHMT (0.69) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL17956289 | 0.93 | BHMT (0.58) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL11575012 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832139 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832141 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL2367840 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL18832137 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 | |
| SCHEMBL2367837 | 0.93 | BHMT (0.70) | BHMTBHMT2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-04-13 | — | — | US | claimed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | claimed |
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | claimed |
| WO-2017189860-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | WO | claimed |
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| US-20050215623-A1 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1531672-A2 | ANTIMICROBIAL COMPOSITIONS | Novus International, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040175434-A1 | Antimicrobial compositions | NOVUS INTERNATIONAL, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004019683-A2 | ANTIMICROBIAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-5439803-A | Using label derived from isotopically substituted glucose to measure relative activities of glycolysis and the pentose phosphate pathway | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1995-08-08 | — | — | US | disclosed |
| US-4055653-A | Sulfur containing trialkoxybenzoylamino carboxylic acids | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-10-25 | — | — | US | disclosed |
| US-3981910-A | Sulfur containing trialkoxybenzoylamino carboxylic acids | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | BHMT 282/4885BHMT2 150/4885NOS2 252/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | BHMT 96/4885BHMT2 68/4885NOS2 864/4885 |
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | BHMT 2/4885BHMT2 1/4885NOS2 477/4885 |
| US-20230111252-A1 | THIOSEMICARBAZATES AND USES THEREOF | TST, ABAT, AADAC | BHMT 154/4885BHMT2 47/4885NOS2 2092/4885 |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | DNPEP, NPEPPS, PAM | BHMT 282/4885BHMT2 150/4885NOS2 252/4885 |
| US-20050215623-A1 | Palatability of aquaculture feed | TAS2R3, TAS2R1, TAS2R20 | BHMT 4314/4885BHMT2 3866/4885NOS2 1172/4885 |
| US-20040175434-A1 | Antimicrobial compositions | MRPL21, FPR1, ARG1 | BHMT 4126/4885BHMT2 4229/4885NOS2 438/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | BHMT 1288/4885BHMT2 880/4885NOS2 26/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | BHMT 85/4885BHMT2 45/4885NOS2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.